Radioligand Therapy (RLT) is an innovative treatment modality in the field of prostate cancer, enriching the therapeutic options. With further research, the personalized application of RLT and its combination with other therapies will become an important direction for the future treatment of prostate cancer. Oncology Frontier invited Dr. Angela Jia, an expert in radiation oncology at the UH Seidman Cancer Center, to share her insights on the role and future potential of RLT and local radiotherapy in the treatment of prostate cancer.

The emergence and evolution of natural orifice specimen extraction surgery (NOSES) in colorectal oncology marks a significant milestone in the journey toward scarless surgery. Since Professor Xishan Wang’s team first…

At the 9th Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee, Dr. Guiyu Wang from The Second Affiliated Hospital of Harbin Medical University delivered a highly anticipated…

At the 9th Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee, Dr. Guanghai Dai from Chinese PLA General Hospital delivered an in-depth presentation on the topic "The…

At the 9th Annual Meeting of the Chinese Medical Doctor Association’s Colorectal Oncology Committee, Dr. Wei Zhang from The First Affiliated Hospital of the Naval Medical University reviewed the 20-year progress in the treatment of low rectal cancer in China and outlined future directions in the field. His presentation highlighted major advancements in organ-preserving surgery, minimally invasive techniques, neoadjuvant therapy, and immunotherapy, showcasing how these innovations have transformed the clinical landscape for low rectal cancer treatment.

With changing dietary habits and the increasing adoption of colorectal cancer screening, the incidence of low rectal cancer is on the rise in China. In Shanghai alone, the annual growth rate is estimated at 4.2% to 4.6%, with 70% to 80% of rectal cancers classified as mid-to-low rectal tumors. Despite advancements in surgical techniques, anastomotic leakage remains a critical challenge, with an incidence ranging from 1.6% to 20%. The risk is particularly pronounced in patients who have undergone neoadjuvant chemoradiotherapy, leading to severe complications such as high mortality rates, serious infections, loss of anal function, and an increased risk of tumor recurrence.

The highly anticipated 19th St. Gallen Breast Cancer Conference (SGBCC) is taking place from March 12 to 15, 2025, in Vienna, Austria, a city renowned for its rich musical heritage. This year’s conference features a special session, "Voice of China," where leading breast cancer experts from CSCO BC share insights into China's clinical, basic, and translational research achievements.

From March 12 to 15, 2025, the 19th St. Gallen Breast Cancer Conference (SGBCC 2025) was held in Vienna, the City of Music. Leading global experts in breast cancer gathered to discuss cutting-edge advancements and hotly debated topics in breast cancer diagnosis and treatment. At the conference, Dr. Javier Cortés, Head of the International Breast Cancer Center (IBCC) in Barcelona, Spain, delivered an insightful keynote speech titled "New anti-HER2 approaches—moving up to the (neo)adjuvant setting?" Oncology Frontier invited Dr. Javier Cortés to share his perspectives and outlook on (neo)adjuvant therapy for early HER2-positive breast cancer.

Breast cancer remains the most prevalent malignancy among women and is the leading cause of cancer-related mortality, posing a significant threat to global women's health. Human epidermal growth factor receptor…